ARWR Plozasiran: 78% Pancreatitis Cut, Presses Ionis

Arrowhead Pharmaceuticals (ARWR) presented full 12-month data from the Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran (REDEMPLO) in severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress on August 30, and the numbers sharpen its pitch against Ionis’ already-approved Tryngolza (olezarsen).

Plozasiran, a quarterly RNAi shot, cut triglycerides by a median 79% in SHASTA-3 and 81% in SHASTA-4 at month 12 (p<0.0001). More than 90% of treated patients reached triglycerides below 500 mg/dL, the threshold for pancreatitis risk, and more than half fell below 150 mg/dL. Across the pooled studies, plozasiran reduced acute pancreatitis events by 78% (relative risk 0.22, p=0.008), a 4.1% absolute cut equal to one event prevented for every 24 patients treated for a year. In the highest-risk subgroup, triglycerides above 500 mg/dL plus a prior pancreatitis, the reduction reached 91%, preventing one event for every three patients treated.

Both drugs lower triglycerides by suppressing APOC3, a liver protein that slows the body’s breakdown of fat-carrying particles, but through different chemistries: plozasiran is a small-interfering RNA, Tryngolza an antisense drug. The market is large. More than 3 million people in the US have sHTG, including about 1 million at high risk of the acute pancreatitis attacks that can mean repeated hospitalizations — and the field is still expanding, with the Lisata-Marea reverse merger bringing an ANGPTL4 antibody into the race.

Arrowhead’s safety case is the story. Serious treatment-emergent adverse events ran 8.3% for plozasiran versus 10% for placebo, discontinuations were 1.4%, and there were no meaningful liver-enzyme or hepatic-fat changes, a contrast to Tryngolza’s liver-enzyme warnings. One wrinkle: worsening glycemic control appeared in 14.3% of treated patients versus 8.7% on placebo, though average HbA1c stayed stable. Three deaths, two cardiovascular and one leukemia, were judged unrelated to the drug.

The caveat is that these are cross-trial comparisons, and analysts read the two drugs’ efficacy as similar. Arrowhead’s differentiation rests on quarterly dosing (versus Tryngolza’s monthly) and safety, not on a bigger triglyceride number. Tryngolza won FDA approval for sHTG in June 2026 and booked $32 million in first-half US sales. The voucher cost an estimated $75 million to $110 million but can shorten FDA review from ten months to six. The stock sits near $84.91. Arrowhead plans an sNDA for the broader sHTG population before year-end, using the Priority Review Voucher it bought in August to speed review, after the plozasiran SHASTA-3/4 topline results in July. Read the full data announcement.

What to watch next: the year-end sNDA filing, which starts the head-to-head with Tryngolza for the sHTG market in earnest.

What It Means for the Trade

The pancreatitis data are the part that changes the commercial story, and it’s worth being precise about why. Triglyceride-lowering numbers win biomarker arguments; pancreatitis-event reductions win labels, payer conversations, and prescribing behavior. The 78% relative reduction in pooled events (RR 0.22, p=0.008), and especially the 91% reduction in the highest-risk subgroup (one event prevented per three patients treated), gives Arrowhead the kind of clinical-outcomes evidence that Ionis’ Tryngolza launch — currently a $32 million first-half run-rate against a June 2026 approval — has not yet had to compete against. If plozasiran’s sNDA lands with pancreatitis-reduction language in the label, the positioning shifts from “another TG-lowerer” to “the one that prevented hospitalizations,” which is a different conversation entirely in a market of 3 million sHTG patients, a million of them high-risk.

The competition math is nevertheless sobering for Arrowhead bulls. Tryngolza has first-mover advantage with a live sales force, established payer coding, and the education groundwork done. Cross-trial efficacy comparisons read as similar (both suppress APOC3 hard; olezarsen’s Phase 3 data showed comparable TG reductions in the 50-60% range with the same >500 mg/dL threshold effects). Arrowhead’s claimed edges: quarterly versus monthly dosing (a real adherence advantage in a chronic asymptomatic-ish population), and the safety profile — 8.3% serious TEAEs versus 10% on placebo with no liver signal, against Tryngolza’s hepatic-enzyme warnings that complicate primary-care prescribing. But a launch against an incumbent in a market that incumbent created is a grind, and ARWR at ~$85 carries substantial platform value (the broader RNAi pipeline and Targeted RNAi Molecule technology partnerships) beyond this single race — the stock trades on more than plozasiran.

The voucher spending is the tell about seriousness: paying an estimated $75-110 million for a Priority Review Voucher to compress review from ten months to six is what a company does when it believes every season of exclusive-market time matters — or when it fears Tryngolza will entrench before plozasiran arrives. Both readings imply management sees the head-to-head as close and winnable.

Mechanism Context: Two Ways to Silence the Same Gene

The APOC3 biology explains why both companies are attacking the same target. Apolipoprotein C-III sits on triglyceride-rich lipoproteins and does two harmful things: it blocks lipoprotein lipase (the enzyme that clears TG from circulation) and it slows hepatic clearance of remnant particles. Suppressing APOC3 accelerates clearance of both TG and the atherogenic remnants — which is why the class also carries cardiovascular implications (the remnant-lowering effect is the mechanism behind the cardiovascular-outcomes interest that followed pelacarsen’s failure in Lp(a) — different target, same lipid-residual-risk logic). Plozasiran does it with siRNA (RNA-induced silencing complex degrades the mRNA, one quarterly shot sustains months of knockdown via the loading of hepatocyte RNA machinery); olezarsen with an antisense oligonucleotide (RNase H-mediated degradation, monthly dosing). Same gene, different chemistry, different pharmacokinetic tails — hence the dosing-interval wedge.

Watch one mechanistic wrinkle in the data: the glycemic signal (14.3% vs 8.7% worsening glucose tolerance). APOC3 biology intersects with glucose-insulin dynamics in ways that have shown up across the class; if the FDA requires glycemic monitoring language in the label, it blunts part of the safety-differentiation story. Average HbA1c stability suggests it’s manageable, but it’s the one place the clean safety case has an asterisk.

Risks and What Could Go Wrong

(1) Filing-to-label translation. The pancreatitis pooled analysis is compelling but was a secondary/pooled construct across two trials; if the FDA restricts the label to TG-lowering without outcomes language, the commercial pitch weakens materially. (2) Tryngolza’s incumbency compounding. By the time plozasiran could launch (late 2027 at the earliest with a PRV-accelerated review), Tryngolza could be on guideline lists and payer formularies with a year of real-world data. (3) The broader APOC3 race. Ionis is not standing still (an oral APOC3 program and lifecycle work around olezarsen), and the cardiovascular-outcomes crowd (Amgen, Lilly in Lp(a)) has painted the lipid-space competitive map an unforgiving shade. (4) Cross-trial comparison risk. Arrowhead’s safety story rests on comparing its trial to Ionis’ trial, not head-to-head data; a skeptical payer or the FDA can dismiss it as non-evidence. (5) ARWR platform dependence. The stock’s multiple embeds the whole RNAi platform thesis; a plozasiran commercial disappointment would ripple into how the pipeline’s other programs (fazirsiran, the cardiometabolic set) are valued.

Position: the data strengthened the story, the filing cadence (year-end sNDA, PRV in hand) is set, and the trade from here is the approval decision and the label language — read the label, not the launch, as the first verdict.